Tempus AI Inc. (NASDAQ:TEM) is a prominent player in the field of AI-driven precision medicine. The company focuses on integrating artificial intelligence technologies into healthcare to improve patient outcomes. Tempus collaborates with major pharmaceutical companies to enhance the discovery and development of precision medicine biomarkers. Its advanced Lens Platform and extensive library of de-identified multimodal data are key assets in these efforts.
On March 10, 2026, Yi Chen from H.C. Wainwright set a price target of $95 for Tempus, while the stock was trading at $52.03. This suggests a potential increase of approximately 82.6%. Despite this optimistic outlook, the stock recently traded at $51.85, reflecting a slight decrease of about 0.90% or $0.47. The stock has fluctuated between $51.73 and $52.93 during the trading day.
Tempus has entered a strategic collaboration with Merck & Co. Inc. (NYSE:MRK) to advance AI-driven precision medicine. This multi-year agreement aims to enhance the discovery and development of precision medicine biomarkers. The partnership will utilize Tempus' advanced Lens Platform, supported by one of the industry's largest GPU infrastructures, to conduct complex analyses.
This collaboration is expected to bolster Merck's oncology and potentially broader therapeutic portfolios by identifying novel precision biomarkers and mechanisms of cancer cell resistance. Despite the significance of this partnership, Tempus' stock experienced a decline, coinciding with broader market sell-offs, as major indices like the S&P 500 and Nasdaq traded lower.
Tempus' market capitalization stands at approximately $8.96 billion, with a trading volume of around 928,414 shares on the NASDAQ exchange. Over the past year, the stock has reached a high of $104.32 and a low of $36.22. This strategic move with Merck highlights Tempus' dedication to integrating AI technologies into healthcare, aiming to improve patient outcomes.
